NYXH(NYXH)
NYXH
ANALYST COVERAGE5 analysts
BUY
▲ +111.3%upside to target
L $5.00
Med $6.00consensus
H $7.00Key MetricsTTM
Market Cap$92.31M
Revenue TTM$16.32M
Net Income TTM-$86.12M
Free Cash Flow-$73.28M
Gross Margin48.3%
Operating Margin-527.2%
Net Margin-527.8%
Return on Equity-164.4%
Return on Assets-87.9%
Debt / Equity1.01
Current Ratio0.99
EPS TTM$-1.99
PRICE
Prev Close
2.86
Open
2.90
Day Range2.84 – 2.90
2.84
2.90
52W Range2.72 – 8.64
2.72
8.64
2% of range
VOLUME & SIZE
Avg Volume
52.1K
FUNDAMENTALS
P/E Ratio
-1.1x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
TECHNICAL
RSI (14)
29
Oversold
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
PDividend Pay
In 159 days
Oct 27
NYXH News
About
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Sector
Industry
Surgical and Medical Instrument Manufacturing
CEO
Olivier Taelman
Country
Belgium
Website
John LandryChief Financial Officer
Maurits S. BoonChief Medical Officer
Bruno OnkelinxChief Technical Officer
Scott HolstineChief Commercial Officer
Geeta KavetiChief Compliance Officer
Maggie McGowanChief HR Officer
Jeyakumar SubbaroyanChief Science Officer
Loic MoreauPresident of International
Olivier TaelmanChief Executive Officer & Executive Director
Remi RenardChief of Staff
Robert TaubCo-Founder & Chairman
An MoonenGeneral Counsel
Pearson DennisInvestor Relations Associate